Compare Adaptive Biotechnologies Corp (ADPT) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Omnicom Group Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Omnicom Group Inc. trades at $78.84 (market cap $23.04B). The key difference: Omnicom Group Inc. is far larger — about 6.9× Adaptive Biotechnologies Corp's market cap, and Omnicom Group Inc. pays a 3.96% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | OMC | |
|---|---|---|
Market Cap | $3.33B | $23.04B |
Sector | Health | Media |
52-Week High | $22.37 | $85.80 |
52-Week Low | $10.24 | $67.27 |
Enterprise Value | $3.19B | $30.27B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
OMC trades at $80.84, up 2.82% today, with a bullish technical outlook supported by moving averages and a consensus price target of $105.75. Recent Q1 2026 earnings beat expectations with EPS of $1.90 versus $1.82 expected, while revenue grew to $17.27B in 2025. The company announced new partnerships with IBM and Netflix, enhancing its media agency footprint, and declared a $0.80 dividend payable in July 2026.
The stock presents value with a low P/E of 12.16 and P/S of 0.93, but net income turned negative in 2025, posing a risk. Analyst sentiment is mixed with 32% buy ratings, reflecting optimism about growth initiatives against profitability concerns. Investors should weigh the attractive valuation and strong cash flow against execution risks in a competitive advertising market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
